Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, whether his Department plans to make lenalidomide available after the Patient Access Scheme for second line treatment is approved.

Ministers are responsible for agreeing whether a patient access scheme (PAS) proposal can be considered in the development of guidance by the National Institute for Health and Care Excellence (NICE), taking advice from the Patient Access Scheme Liaison Unit at NICE into account. It is then for NICE to consider the PAS proposal alongside other evidence in determining whether the technology represents a clinical and cost effective use of National Health Service resources taking into account.

In line with the provisions of the 2014 Pharmaceutical Price Regulation Scheme, discussions about patient access scheme proposals are confidential until a proposal is considered in the development of NICE guidance.